ストックスクリーナーアプリを入手
3.75
2.41%
0.02
前日終値:
$3.73
開ける：
$3.79
24時間の取引高:
3,746
Relative Volume:
0.05
時価総額：
$35.18M
収益：
$4.01M
当期純損益:
$-26.97M
株価収益率:
-1.2623
EPS:
-2.9707
ネットキャッシュフロー:
$-23.45M
1週間 パフォーマンス:
+4.66%
1か月 パフォーマンス:
-4.02%
6か月 パフォーマンス:
-47.60%
1年 パフォーマンス:
-59.28%
1日の値動き範囲:
$3.75
$3.8899
1週間の範囲:
$3.61
$3.986
52週間の値動き範囲:
$3.51
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Compare CRVO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.80 | 34.54M | 4.01M | -26.97M | -23.45M | -2.9707 |
VRTX
Vertex Pharmaceuticals Inc
|
426.60 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
723.08 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.42 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.45 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.08 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-13 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-12-05 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-18 | 開始されました | Chardan Capital Markets | Buy |
| 2024-07-26 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-15 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Cervomed Inc (CRVO) 最新ニュース
CRVO Stock Price, Quote & Chart | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CervoMed (CRVO) outlines 2026 virtual meeting, board slate and pay plan vote - Stock Titan
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CRVO (CervoMed) posts wider than expected Q4 2025 loss even as shares notch mild daily gains.Crowd Risk Alerts - Newser
CRVO Maintained by D. Boral Capital -- Price Target Steady at $3 - GuruFocus
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results - TipRanks
CRVO (CervoMed Inc.) reports wider-than-expected Q4 2025 loss driven by elevated clinical research spending.Decline Phase - Cổng thông tin điện tử Tỉnh Sơn La
Neflamapimod MRI data in dementia with Lewy bodies from CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Shows Promise in DLB Treatment with Neflamapimod - GuruFocus
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - ChartMill
What should investors watch for CervoMed (CRVO) stock (Smart Money Exits) 2026-04-20Public Sentiment - Cổng thông tin điện tử tỉnh Lào Cai
Is CervoMed (CRVO) stock a good candidate for diversification (Investor Concern) 2026-04-18Community Pattern Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Operating cash flow per share of CervoMed Inc. – FWB:DP8 - TradingView — Track All Markets
CRVO Should I Buy - Intellectia AI
CRVO.O PE Ratio & Valuation, Is CRVO.O Overvalued - Intellectia AI
CRVO.O Forecast — Price Prediction for 2026. Should I Buy CRVO.O? - Intellectia AI
Buyout Rumor: Does CervoMed Inc have strong fundamentalsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
CRVO.O Technical Analysis & Stock Price Forecast - Intellectia AI
CRVO.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lewy Body Dementia Market: Accelerating Growth And Pipeline Impact By 2034 Delveinsight Cognition Therapeutics, Keiferx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Mena FN
Lewy Body Dementia Market: Accelerating Growth and Pipeline - openPR.com
CervoMed Inc. prepares Phase 3 trial after CEO engages on advancing dementia biomarkers - Traders Union
CervoMed (CRVO) Maintains "Buy" Rating with $31 Price Target | C - GuruFocus
CervoMed Inc. Provides Neflamapimod Clinical Program Update and Announces Participation at 2026 Lewy Body Dementia Association Annual Meeting - Minichart
Is CervoMed (CRVO) Stock Lagging the Market | Price at $3.79, Down 1.38%Community Breakout Alerts - Newser
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia - TipRanks
AWM-owned funds hold 405,165 shares in CervoMed (CRVO) — 4.2% stake - Stock Titan
Form 8-KCurrent report - ADVFN
CervoMed Inc. Announces Neflamapimod Clinical Trial Updates and MRI Findings at Lewy Body Dementia Association Meeting - Quiver Quantitative
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - ChartMill
CRVO PE Ratio & Valuation, Is CRVO Overvalued - Intellectia AI
CRVO.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CRVO News & Events - Intellectia AI
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com
CRVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
CRVO Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Buy: How do insiders feel about CervoMed IncPrice Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CervoMed (CRVO)’s Q4 results feature advancements in its neflamapimod program for dementia Lewy bodies (DLB) - MSN
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB) - Insider Monkey
CEO Change: Is CervoMed Inc stock overvalued or fairly priced2026 Technicals & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Top 5 Stocks Under $5 That Could Triple - insidermonkey.com
CervoMed Posts Investor Presentation Under Regulation FD Disclosure - TipRanks
CRVO: Phase III DLB trial launches this year, leveraging biomarker-driven selection and robust phase II data - TradingView
CervoMed (NASDAQ: CRVO) furnishes updated investor presentation via 8-K - Stock Titan
Cervomed Inc (CRVO) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):